CollaGenex Reports Mixed Results From Rosacea Drug Study
Posted on: Friday, 28 September 2007, 12:01 CDT
CollaGenex Pharmaceuticals has reported mixed results from a Phase II dose-finding study of Incyclinide, an experimental rosacea treatment.
The study demonstrated that incyclinide was well-tolerated, with most adverse events being mild or moderate.
However, the patients who were administered incyclinide did not demonstrate a greater reduction in inflammatory lesions than the patients on placebo at any time point during the study.
The double-blind, placebo-controlled trial enrolled a total of 197 moderate-to-severe rosacea patients at 19 centers.
Klaus Theobald, chief medical officer of CollaGenex, said: "They are surprised and disappointed that the results of this large, well-controlled Phase II study did not support the findings of an earlier, much smaller pilot study in rosacea patients. On the basis of these results, they will not be pursuing further clinical development of Incyclinide in rosacea patients."
Colin Stewart, president and CEO of CollaGenex, said: "While clinical disappointments are to be expected in pharmaceutical development, CollaGenex will continue to focus on developing its robust product pipeline. They recently announced outstanding clinical results in their large Phase II study of Col-118 in the treatment of erythema, and we expect to initiate Phase III clinical studies of Col-118 very early in 2008."
Source: Datamonitor
Related Articles
- Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
- Ambrilia Reports Positive Final Phase III Results for Its Octreotide Formulation C2L
- Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate Its Diclofenac Patch for Mild to Moderate Pain
- Cutanea Announces Promising Phase II Results in Rosacea With Omiganan
- Biothera Initiates Phase Ib/IIa Clinical Trial With Imprime PGG and Erbitux in Metastatic Colorectal Cancer Patients
- ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From Its U.S. Phase II/III Clinical Study Of Bepotastine
- Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft Vs. Host Disease
- InterMune Enrolls 600th Patient in Phase III INSPIRE Clinical Trial
- Oxford Biomedica Plc Announces Oxford BioMedica Presents Encouraging Final Phase II Results With Trovax(R) in Colorectal Cancer at the International Colorectal Cancer Congress
 |
 |
User Comments (0)
RSS Feeds